THERAVLINFO (INTERREG-POCTEFA program EFA123/1) is a multidisciplinary network that seeks to strengthen cooperation among 4 previous partners (2 hospitals and 2 research centers in Barcelona and Toulouse) and foster new synergies with 1 research center in Navarra. Additionally, it collaborates with 2 biotech companies within the POCTEFA territory.

IMLINFO enabled us to establish a repository of samples from non-Hodgkin lymphoma (NHL) patients, develop a 3D culture platform that recapitulates the disease in vitro, and create a workflow for conducting antitumor drug screenings. Targets involved in the evasion of antitumor immune response and immunosuppression were identified.

THERAVLINFO will improve the 3D systems, develop drugs targeting these pathways (antibodies, CAR-T cell therapy, and nanocapsules), and validate their therapeutic potential in murine models.

THERAVLINFO includes the collaboration of experts in multicellular 3D cultures, animal models, multiparametric flow cytometry, confocal microscopy, omics technologies, and computational analysis, and aims to promote the training of young researchers who can integrate and rotate among the cross-border partners.

It develops cellular therapies with Hospital Clinic of Barcelona and fosters collaborations with companies for the development of antibody-based immunotherapies (ONA Therapeutics) and new oral bioavailability and delivery systems for antibodies (NUCAPS). Aiming to advance toward personalized medicine for NHL patients who do not respond to standard treatment, experience early relapses, or transform into aggressive lymphoma, cross-border cooperation is essential to obtain material from these patients in hospitals and to develop new therapies.